Literature DB >> 6716271

Effects of N-nitrosodimethylamine on humoral immunity.

M P Holsapple, A N Tucker, P J McNerney, K L White.   

Abstract

Female B6C3F1 mice were given i.p. injections with 1.5, 3.0 and 5.0 mg/kg N-nitrosodimethylamine (DMN) daily for 14 days and evaluated on day 15. The day 4 immunoglobulin M (peak day) antibody response to sheep red blood cells (sRBC) was inhibited by 20, 53 and 81%, respectively. The day 5 immunoglobulin G (peak day) antibody response to sRBC was only inhibited significantly (60%) at the highest dose. Recovery studies indicated that the IgM antibody response was still significantly inhibited (48%) 30 days after the completion of the exposure to 5 mg/kg of DMN. The peak response (day 3) to 100 micrograms of the B-cell mitogen, lipopolysaccharide, was inhibited by 15, 26 and 32%, respectively, indicating that a portion of the suppression of the antibody response by DMN may be due to an effect on the ability of the lymphocytes to proliferate. Concentrations of DMN up to 100 mM added directly to untreated spleen cell suspensions had no effect on the in vitro antibody responses to lipopolysaccharide and sRBC. Preincubating DMN (100 mM) with either phenobarbital-induced or 3-methylcholanthrene-induced liver proteins (postmitochondrial supernatant from a 9000 X g liver homogenate) was still ineffective. The activation of DMN by either preparation was verified by measuring formaldehyde production, which reflects demethylation. In contrast to the results with DMN added directly to untreated spleen cell suspensions, the most sensitive indicator of suppression by DMN was the in vitro antibody responses to lipopolysaccharide and sRBC by spleen cell suspensions from DMN-treated mice.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6716271

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Immunotoxicology.

Authors:  K Miller
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

2.  cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1.

Authors:  K W Johnson; B H Davis; K A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

3.  Measurement of modulation of mouse complement levels in vivo, utilizing a microtiter hemolytic assay.

Authors:  K L White; A C Anderson
Journal:  Agents Actions       Date:  1984-12

4.  TCDD-mediated suppression of the in vitro anti-sheep erythrocyte IgM antibody forming cell response is reversed by interferon-gamma.

Authors:  Colin M North; Byung-Sam Kim; Neil Snyder; Robert B Crawford; Michael P Holsapple; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2008-10-22       Impact factor: 4.849

5.  Simultaneous in vivo time course and dose response evaluation for TCDD-induced impairment of the LPS-stimulated primary IgM response.

Authors:  Colin M North; Robert B Crawford; Haitian Lu; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2009-08-12       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.